@article{10707,
  keywords = {Anticoagulants, Apixaban, Atrial fibrillation, Cprd, Dabigatran, Edoxaban, Rivaroxaban, Stroke prevention and control, United Kingdom},
  author = {A. Khachatryan and I. Doobaree and G. Spentzouris and G. Gusto and Y. Zawaneh and F. Mughal and A. Anastassopoulou and M. Manu and M. Fay},
  title = {Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database},
  year = {2022},
  journal = {Adv Ther},
  edition = {2022/11/19},
  isbn = {0741-238x},
  doi = {10.1007/s12325-022-02368-y},
  note = {1865-8652
Khachatryan, Artak
Doobaree, Indraraj Umesh
Spentzouris, George
Gusto, Gaelle
Zawaneh, Yousef
Mughal, Farhan
Anastassopoulou, Anastassia
Manu, Marius
Fay, Matthew
Journal Article
United States
Adv Ther. 2022 Nov 18. doi: 10.1007/s12325-022-02368-y.},
  language = {eng},
}